Gene Set Enrichment Analysis of the Bronchial Epithelium Implicates
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells
Published OnlineFirst May 2, 2019; DOI: 10.1158/2159-8290.CD-19-0125 RESEARCH ARTICLE The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells Tamilla Nechiporuk1,2, Stephen E. Kurtz1,2, Olga Nikolova2,3, Tingting Liu1,2, Courtney L. Jones4, Angelo D’Alessandro5, Rachel Culp-Hill5, Amanda d’Almeida1,2, Sunil K. Joshi1,2, Mara Rosenberg1,2, Cristina E. Tognon1,2,6, Alexey V. Danilov1,2, Brian J. Druker1,2,6, Bill H. Chang2,7, Shannon K. McWeeney2,8, and Jeffrey W. Tyner1,2,9 ABSTRACT To study mechanisms underlying resistance to the BCL2 inhibitor venetoclax in acute myeloid leukemia (AML), we used a genome-wide CRISPR/Cas9 screen to identify gene knockouts resulting in drug resistance. We validated TP53, BAX, and PMAIP1 as genes whose inactivation results in venetoclax resistance in AML cell lines. Resistance to venetoclax resulted from an inability to execute apoptosis driven by BAX loss, decreased expression of BCL2, and/or reliance on alternative BCL2 family members such as BCL2L1. The resistance was accompanied by changes in mitochondrial homeostasis and cellular metabolism. Evaluation of TP53 knockout cells for sensitivities to a panel of small-molecule inhibitors revealed a gain of sensitivity to TRK inhibitors. We relate these observations to patient drug responses and gene expression in the Beat AML dataset. Our results implicate TP53, the apoptotic network, and mitochondrial functionality as drivers of venetoclax response in AML and suggest strategies to overcome resistance. SIGNIFICANCE: AML is challenging to treat due to its heterogeneity, and single-agent therapies have universally failed, prompting a need for innovative drug combinations. -
TOX2 Is Differentially Expressed in Non-Small Cell Lung Cancer-PDF 092220
1 Tox2 is differentially expressed in non-small cell lung cancer and associates with patient 2 survival. 3 Shahan Mamoor1 4 [email protected] East Islip, NY USA 5 6 Non-small cell lung cancer (NSCLC) is the leading cause of cancer death in the United States1. 7 We mined published microarray data2,3,4 to identify differentially expressed genes in NSCLC. 8 We found that the gene encoding the thymyocyte selection-associated high mobility box protein 9 family member 2 transcription factor Tox2 was among the genes whose expression was most quantitatively different in tumors from patients with NSCLC as compared to the lung. Tox2 10 expression was significantly decreased in NSCLC tumors as compared to the lung, and lower 11 expression of Tox2 in patient tumors was significantly associated with worse overall survival. Tox2 may be important for initiation or progression of non-small cell lung cancer in humans. 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 Keywords: Tox2, NSCLC, non-small cell lung cancer, systems biology of NSCLC, targeted 27 therapeutics in NSCLC. 28 1 OF 16 1 In 2016, lung cancer resulted in the death of 158,000 Americans; 81% of all patients 2 diagnosed with lung cancer will expire within 5 years5. Non-small cell lung cancer (NSCLC) is 3 4 the most common type of lung cancer, diagnosed in 84% of patients with lung cancer, and 76% 5 of all patients with NSCLC will expire within 5 years5. The rational development of targeted 6 therapeutics to treat patients with NSCLC can be supported by an enhanced understanding of 7 8 fundamental transcriptional features of NSCLC tumors. -
TOX As a Potential Target for Immunotherapy in Lymphocytic Malignancies Chaofeng Liang1,2, Shuxin Huang1, Yujie Zhao1, Shaohua Chen1* and Yangqiu Li1*
Liang et al. Biomarker Research (2021) 9:20 https://doi.org/10.1186/s40364-021-00275-y REVIEW Open Access TOX as a potential target for immunotherapy in lymphocytic malignancies Chaofeng Liang1,2, Shuxin Huang1, Yujie Zhao1, Shaohua Chen1* and Yangqiu Li1* Abstract TOX (thymocyte selection-associated HMG BOX) is a member of a family of transcriptional factors that contain the highly conserved high mobility group box (HMG-box) region. Increasing studies have shown that TOX is involved in maintaining tumors and promoting T cell exhaustion. In this review, we summarized the biological functions of TOX and its contribution as related to lymphocytic malignancies. We also discussed the potential role of TOX as an immune biomarker and target in immunotherapy for hematological malignancies. Keywords: Thymocyte selection-associated HMG BOX, Biological function, T cell exhaustion, Lymphocytic malignancies, Immune biomarker, Immunotherapy Background located on different chromosomes and have different TOX (thymocyte selection-associated HMG BOX), a functions (Fig. 1, Table 1)[16]. transcription factor, belongs to the high mobility group box (HMG-box) superfamily. In 2002, Wilkinson et al. TOX demonstrated for the first time that TOX plays an im- TOX, also known as KIAA0808, is located on q12.1 of portant role in the differentiation of CD4 + CD8+ human chromosome 8 and has one transcript. The double-positive thymocytes by gene microarray technol- length of the TOX mRNA is 4076 bp, and it contains ogy. Numerous studies have shown that TOX plays a nine exons that translate into a protein consisting of 526 vital role in the development and formation of various amino acids. -
Transcriptome Analyses of Rhesus Monkey Pre-Implantation Embryos Reveal A
Downloaded from genome.cshlp.org on September 23, 2021 - Published by Cold Spring Harbor Laboratory Press Transcriptome analyses of rhesus monkey pre-implantation embryos reveal a reduced capacity for DNA double strand break (DSB) repair in primate oocytes and early embryos Xinyi Wang 1,3,4,5*, Denghui Liu 2,4*, Dajian He 1,3,4,5, Shengbao Suo 2,4, Xian Xia 2,4, Xiechao He1,3,6, Jing-Dong J. Han2#, Ping Zheng1,3,6# Running title: reduced DNA DSB repair in monkey early embryos Affiliations: 1 State Key Laboratory of Genetic Resources and Evolution, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650223, China 2 Key Laboratory of Computational Biology, CAS Center for Excellence in Molecular Cell Science, Collaborative Innovation Center for Genetics and Developmental Biology, Chinese Academy of Sciences-Max Planck Partner Institute for Computational Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China 3 Yunnan Key Laboratory of Animal Reproduction, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650223, China 4 University of Chinese Academy of Sciences, Beijing, China 5 Kunming College of Life Science, University of Chinese Academy of Sciences, Kunming, Yunnan 650204, China 6 Primate Research Center, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, 650223, China * Xinyi Wang and Denghui Liu contributed equally to this work 1 Downloaded from genome.cshlp.org on September 23, 2021 - Published by Cold Spring Harbor Laboratory Press # Correspondence: Jing-Dong J. Han, Email: [email protected]; Ping Zheng, Email: [email protected] Key words: rhesus monkey, pre-implantation embryo, DNA damage 2 Downloaded from genome.cshlp.org on September 23, 2021 - Published by Cold Spring Harbor Laboratory Press ABSTRACT Pre-implantation embryogenesis encompasses several critical events including genome reprogramming, zygotic genome activation (ZGA) and cell fate commitment. -
Dissertation
Dissertation submitted to the Combined Faculty of Natural Sciences and Mathematics of the Ruperto Carola University Heidelberg, Germany for the degree of Doctor of Natural Sciences Presented by Elisabeth Drucker, M.Sc. born in: Vienna, Austria Oral examination: 05/15/2019 FUNCTIONAL AND MECHANISTIC CHARACTERIZATION OF THE NUCLEAR IMPORT RECEPTOR KARYOPHERIN-α2 IN LIVER CANCER Referees: Prof. Dr. Ursula Klingmüller Prof. Dr. Kai Breuhahn For my mom, a woman who cherished the merit of wisdom. ABBREVIATIONS ABBREVIATIONS AASLD American Association for the Study of Liver Diseases AFLD Alcoholic fatty liver disease ASH Alcoholic steatohepatitis ATF-2 Activating transcription factor 2 BCLC Barcelona Clinic Liver Cancer BSA Bovine serum albumin CAS Cellular apoptosis susceptibility (also XPO2) CDC2 Cell division cycle protein 2 homolog (gene, also CDK1 (protein)) ChIP Chromatin immunoprecipitation ChIP-Seq ChIP (DNA) sequencing CoIP Co-immunoprecipitation CTNNB1 β-catenin COX2 Cyclooxygenase 2 CRM1 Chromosomal maintenance 1 (also XPO1) ctrl Control DMEM Dulbecco’s Modified Eagle Medium DMSO Dimethyl sulfoxide EASL European Association for the Study of the Liver EDTA Ethylenediaminetetraacetic acid FBP-1/2 Fuse binding protein 1/2 FCS Fetal calf serum FFPE Formalin-fixed paraffin-embedded FIR FBP-interacting repressor GMPS Guanosine monophosphate synthetase GTSF1 Gametocyte-specific factor 1 i ABBREVIATIONS HBV Hepatitis B virus HCV Hepatitis C virus HCC Hepatocellular carcinoma HGF Hepatocyte growth factor HMOX1 Heme oxygenase 1 H&E Hematoxylin -
DP1 (TFDP1) (NM 007111) Human Untagged Clone Product Data
OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for SC127935 DP1 (TFDP1) (NM_007111) Human Untagged Clone Product data: Product Type: Expression Plasmids Product Name: DP1 (TFDP1) (NM_007111) Human Untagged Clone Tag: Tag Free Symbol: TFDP1 Synonyms: DILC; Dp-1; DP1; DRTF1 Vector: pCMV6-XL4 E. coli Selection: Ampicillin (100 ug/mL) Cell Selection: None Fully Sequenced ORF: >OriGene ORF within SC127935 sequence for NM_007111 edited (data generated by NextGen Sequencing) ATGGCAAAAGATGCCGGTCTAATTGAAGCCAACGGAGAACTCAAGGTCTTCATAGACCAG AACCTTAGTCCCGGGAAAGGCGTGGTGTCCCTCGTGGCCGTTCACCCCTCCACCGTCAAC CCGCTCGGGAAGCAGCTCTTGCCAAAAACCTTTGGACAGTCCAATGTCAACATTGCCCAG CAAGTGGTAATTGGTACGCCTCAGAGACCGGCAGCGTCAAACACCCTGGTGGTAGGAAGC CCACACACCCCCAGCACTCACTTTGCCTCTCAGAACCAGCCTTCCGACTCCTCACCTTGG TCTGCCGGGAAGCGCAACAGGAAAGGAGAGAAGAATGGCAAGGGCCTACGGCATTTCTCC ATGAAGGTCTGCGAGAAGGTGCAGAGGAAAGGGACCACTTCCTACAACGAAGTGGCAGAC GAGCTGGTTGCGGAGTTCAGTGCTGCCGACAACCACATCTTACCAAACGAGTCAGCTTAT GACCAGAAAAACATAAGACGGCGCGTCTACGATGCCTTAAACGTGCTAATGGCCATGAAC ATCATCTCCAAGGAGAAGAAGGAGATCAAGTGGATTGGTCTGCCCACCAACTCGGCTCAG GAATGTCAGAACTTAGAGGTGGAAAGACAGAGGAGACTTGAAAGAATAAAACAGAAACAG TCTCAACTTCAAGAACTTATTCTACAGCAAATTGCCTTCAAGAACCTGGTGCAGAGAAAC CGGCATGCGGAGCAGCAGGCCAGCCGGCCACCGCCACCCAACTCAGTCATCCACCTGCCC TTCATCATCGTCAACACCAGCAAGAAGACGGTCATCGACTGCAGCATCTCCAATGACAAA TTTGAGTATCTGTTTAATTTTGACAACACATTTGAAATCCACGATGACATAGAAGTGCTG AAGCGGATGGGCATGGCTTGCGGGCTGGAGTCGGGGAGCTGCTCTGCCGAAGACCTTAAA -
Transcriptional Control of Tissue-Resident Memory T Cell Generation
Transcriptional control of tissue-resident memory T cell generation Filip Cvetkovski Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Graduate School of Arts and Sciences COLUMBIA UNIVERSITY 2019 © 2019 Filip Cvetkovski All rights reserved ABSTRACT Transcriptional control of tissue-resident memory T cell generation Filip Cvetkovski Tissue-resident memory T cells (TRM) are a non-circulating subset of memory that are maintained at sites of pathogen entry and mediate optimal protection against reinfection. Lung TRM can be generated in response to respiratory infection or vaccination, however, the molecular pathways involved in CD4+TRM establishment have not been defined. Here, we performed transcriptional profiling of influenza-specific lung CD4+TRM following influenza infection to identify pathways implicated in CD4+TRM generation and homeostasis. Lung CD4+TRM displayed a unique transcriptional profile distinct from spleen memory, including up-regulation of a gene network induced by the transcription factor IRF4, a known regulator of effector T cell differentiation. In addition, the gene expression profile of lung CD4+TRM was enriched in gene sets previously described in tissue-resident regulatory T cells. Up-regulation of immunomodulatory molecules such as CTLA-4, PD-1, and ICOS, suggested a potential regulatory role for CD4+TRM in tissues. Using loss-of-function genetic experiments in mice, we demonstrate that IRF4 is required for the generation of lung-localized pathogen-specific effector CD4+T cells during acute influenza infection. Influenza-specific IRF4−/− T cells failed to fully express CD44, and maintained high levels of CD62L compared to wild type, suggesting a defect in complete differentiation into lung-tropic effector T cells. -
Supplementary Table S5. Differentially Expressed Gene Lists of PD-1High CD39+ CD8 Tils According to 4-1BB Expression Compared to PD-1+ CD39- CD8 Tils
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) J Immunother Cancer Supplementary Table S5. Differentially expressed gene lists of PD-1high CD39+ CD8 TILs according to 4-1BB expression compared to PD-1+ CD39- CD8 TILs Up- or down- regulated genes in Up- or down- regulated genes Up- or down- regulated genes only PD-1high CD39+ CD8 TILs only in 4-1BBneg PD-1high CD39+ in 4-1BBpos PD-1high CD39+ CD8 compared to PD-1+ CD39- CD8 CD8 TILs compared to PD-1+ TILs compared to PD-1+ CD39- TILs CD39- CD8 TILs CD8 TILs IL7R KLRG1 TNFSF4 ENTPD1 DHRS3 LEF1 ITGA5 MKI67 PZP KLF3 RYR2 SIK1B ANK3 LYST PPP1R3B ETV1 ADAM28 H2AC13 CCR7 GFOD1 RASGRP2 ITGAX MAST4 RAD51AP1 MYO1E CLCF1 NEBL S1PR5 VCL MPP7 MS4A6A PHLDB1 GFPT2 TNF RPL3 SPRY4 VCAM1 B4GALT5 TIPARP TNS3 PDCD1 POLQ AKAP5 IL6ST LY9 PLXND1 PLEKHA1 NEU1 DGKH SPRY2 PLEKHG3 IKZF4 MTX3 PARK7 ATP8B4 SYT11 PTGER4 SORL1 RAB11FIP5 BRCA1 MAP4K3 NCR1 CCR4 S1PR1 PDE8A IFIT2 EPHA4 ARHGEF12 PAICS PELI2 LAT2 GPRASP1 TTN RPLP0 IL4I1 AUTS2 RPS3 CDCA3 NHS LONRF2 CDC42EP3 SLCO3A1 RRM2 ADAMTSL4 INPP5F ARHGAP31 ESCO2 ADRB2 CSF1 WDHD1 GOLIM4 CDK5RAP1 CD69 GLUL HJURP SHC4 GNLY TTC9 HELLS DPP4 IL23A PITPNC1 TOX ARHGEF9 EXO1 SLC4A4 CKAP4 CARMIL3 NHSL2 DZIP3 GINS1 FUT8 UBASH3B CDCA5 PDE7B SOGA1 CDC45 NR3C2 TRIB1 KIF14 TRAF5 LIMS1 PPP1R2C TNFRSF9 KLRC2 POLA1 CD80 ATP10D CDCA8 SETD7 IER2 PATL2 CCDC141 CD84 HSPA6 CYB561 MPHOSPH9 CLSPN KLRC1 PTMS SCML4 ZBTB10 CCL3 CA5B PIP5K1B WNT9A CCNH GEM IL18RAP GGH SARDH B3GNT7 C13orf46 SBF2 IKZF3 ZMAT1 TCF7 NECTIN1 H3C7 FOS PAG1 HECA SLC4A10 SLC35G2 PER1 P2RY1 NFKBIA WDR76 PLAUR KDM1A H1-5 TSHZ2 FAM102B HMMR GPR132 CCRL2 PARP8 A2M ST8SIA1 NUF2 IL5RA RBPMS UBE2T USP53 EEF1A1 PLAC8 LGR6 TMEM123 NEK2 SNAP47 PTGIS SH2B3 P2RY8 S100PBP PLEKHA7 CLNK CRIM1 MGAT5 YBX3 TP53INP1 DTL CFH FEZ1 MYB FRMD4B TSPAN5 STIL ITGA2 GOLGA6L10 MYBL2 AHI1 CAND2 GZMB RBPJ PELI1 HSPA1B KCNK5 GOLGA6L9 TICRR TPRG1 UBE2C AURKA Leem G, et al. -
TOX3 Is Expressed in Mammary ER+ Epithelial Cells and Regulates ER
Seksenyan et al. BMC Cancer (2015) 15:22 DOI 10.1186/s12885-015-1018-2 RESEARCH ARTICLE Open Access TOX3 is expressed in mammary ER+ epithelial cells and regulates ER target genes in luminal breast cancer Akop Seksenyan1, Asha Kadavallore1, Ann E Walts2, Brian de la Torre1, Dror Berel3,4, Samuel P Strom5,6, Parinaz Aliahmad1, Vincent A Funari5 and Jonathan Kaye1,3,7* Abstract Background: A breast cancer susceptibility locus has been mapped to the gene encoding TOX3. Little is known regarding the expression pattern or biological role of TOX3 in breast cancer or in the mammary gland. Here we analyzed TOX3 expression in murine and human mammary glands and in molecular subtypes of breast cancer, and assessed its ability to alter the biology of breast cancer cells. Methods: We used a cell sorting strategy, followed by quantitative real-time PCR, to study TOX3 gene expression in the mouse mammary gland. To study the expression of this nuclear protein in human mammary glands and breast tumors, we generated a rabbit monoclonal antibody specific for human TOX3. In vitro studies were performed on MCF7, BT474 and MDA-MB-231 cell lines to study the effects of TOX3 modulation on gene expression in the context of breast cancer cells. Results: We found TOX3 expression in estrogen receptor-positive mammary epithelial cells, including progenitor cells. A subset of breast tumors also highly expresses TOX3, with poor outcome associated with high expression of TOX3 in luminal B breast cancers. We also demonstrate the ability of TOX3 to alter gene expression in MCF7 luminal breast cancer cells, including cancer relevant genes TFF1 and CXCR4. -
TOX3 Is a Favorable Prognostic Indicator and Potential Immunomodulatory Factor in Lung Adenocarcinoma
4144 ONCOLOGY LETTERS 18: 4144-4152, 2019 TOX3 is a favorable prognostic indicator and potential immunomodulatory factor in lung adenocarcinoma DE ZENG1, HAOYU LIN2, JIANXIONG CUI2 and WEIQUAN LIANG2 1Department of Medical Oncology, Cancer Hospital of Shantou University Medical College; 2Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong 515000, P.R. China Received February 13, 2018; Accepted January 14, 2019 DOI: 10.3892/ol.2019.10748 Abstract. Thymocyte selection-associated high mobility and cytotoxic T lymphocyte-associated protein 4 (CTLA4), as group box (TOX) genes represent a novel family of genes. well as the development of novel immunotherapy agents, lung Deregulated expression of TOXs has been reported in a cancer treatments have improved notably in terms of disease variety of cancer types, including lung cancer. It has also control and survival outcomes (3). However, the success rate been reported that TOXs are crucial regulators of the immune of immunotherapy remains low, and a large number of cancer system. The present study systematically evaluated the prog- types, including lung cancer, remain largely insensitive or nostic values of TOX family members using a set of publicly refractory to PD-1, PD-L1 and CTLA4 blockade (2,4-6). accessible databases, including Oncomine, Kaplan-Meier Therefore, research has focused on identifying novel immu- plotter and cBioPortal. It was revealed that TOX expression notherapy targets or immunomodulatory factors that can profiles differed between lung cancer and normal tissues, be exploited to enhance the response to current immuno- and high expression of TOX mRNAs generally predicted therapeutic agents and address immunotherapy resistance in improved survival outcomes. -
University of Florida Thesis Or Dissertation Formatting
TRANSCRIPTIONAL AND EPIGENETIC PROFILING OF THE HIPPOCAMPUS AND THE MEDIAL PREFRONTAL CORTEX: RELATIONSHIP TO AGING AND COGNITIVE DECLINE By LARA IANOV A DISSERTATION PRESENTED TO THE GRADUATE SCHOOL OF THE UNIVERSITY OF FLORIDA IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY UNIVERSITY OF FLORIDA 2017 © 2017 Lara Ianov To my spouse, Okie Ianov, and my dear friends Lana McMillan and Guido Pardi ACKNOWLEDGMENTS First, I would like to thank my mentor, Dr. Thomas C. Foster, for providing me the opportunity to work on an exciting area of research, along with his trust in my skills and his time and patience to mentor me. I would also like to acknowledge my committee members, Dr. Leonid Moroz, Dr. Jorg Bungert and Dr. Martha Campbell-Thompson for their guidance and suggestions in all committee meetings. In addition, Dr. Alberto Riva, deserves special recognition for his devoted support to me with a section of the data analysis shown in this dissertation. I would also like to thank Dr. Jennifer Bizon and Dr. B. Sofia Beas for their help with the set shifting task. Furthermore, I would also like to thank the past and present Genetics and Genomics program coordinators including Dr. Wilfred Vermerris who admitted me into the program, Dr. Jorg Bungert and Dr. Connie Mulligan, as past coordinators, and the current coordinators, Dr. Maurice Swanson and Dr. Doug Soltis. I would also like to thank Dr. Patrick Concannon, for his support to the program and the Genetics Institute. Finally, I would like to thank Hope Parmeter for signing me up for all classes each semester along with all student-related requirements. -
Integrative Prediction of Gene Expression with Chromatin Accessibility and Conformation Data
bioRxiv preprint doi: https://doi.org/10.1101/704478; this version posted July 16, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Integrative prediction of gene expression with chromatin accessibility and conformation data Florian Schmidt1;2;3;y, Fabian Kern1;3;4;y, and Marcel H. Schulz1;2;3;5;6;∗ 1High-throughput Genomics & Systems Biology, Cluster of Excellence on Multimodal Computing and Interaction, Saarland Informatics Campus, 66123 Saarbr¨ucken Germany 2Computational Biology & Applied Algorithmics, Max-Planck Institute for Informatics, Saarland Informatics Campus, 66123 Saarbr¨ucken Germany 3Center for Bioinformatics, Saarland Informatics Campus, 66123 Saarbr¨ucken Germany 4Chair for Clinical Bioinformatics, Saarland Informatics Campus, 66123 Saarbr¨ucken Germany 5Institute of Cardiovascular Regeneration, Goethe-University, Theodor-Stern-Kai 7, 60590 Frankfurt am Main Germany 6German Center for Cardiovascular Research, Partner site Rhein-Main, Theodor-Stern-Kai 7, 60590 Frankfurt am Main Germany y These authors contributed equally ∗ Correspondence: [email protected] Abstract Background: Enhancers play a fundamental role in orchestrating cell state and development. Al- though several methods have been developed to identify enhancers, linking them to their target genes is still an open problem. Several theories have been proposed on the functional mechanisms of en- hancers, which triggered the development of various methods to infer promoter enhancer interactions (PEIs). The advancement of high-throughput techniques describing the three-dimensional organisa- tion of the chromatin, paved the way to pinpoint long-range PEIs.